Next Article in Journal
Prevention and Treatment of Cancer-Associated Thrombosis
Previous Article in Journal
Oncologists and Medical Assistance in Dying: Where Do We Stand? Results of a National Survey of Canadian Oncologists
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations

1
McMaster University and Juravinski Hospital and Cancer Centre, Hamilton, ON, Canada
2
McGill University and Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC, Canada
3
University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada
4
University of Alberta and Cross Cancer Institute, Edmonton, AB, Canada
5
Dalhousie University and Queen Elizabeth ii Health Sciences Centre, Halifax, NS, Canada
6
impact Medicom Inc., Toronto, ON, Canada
7
University of Toronto and Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(5), 270-274; https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.7149
Submission received: 12 July 2020 / Revised: 8 August 2020 / Accepted: 3 September 2020 / Published: 1 October 2020

Abstract

The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that patients with multiple myeloma are at increased risk of covid-19 infection and related complications, national bodies and experts around the globe have made recommendations for risk mitigation strategies for those vulnerable patients. Understandably, because of the novelty of the virus, many of the proposed risk mitigation strategies have thus far been reactionary and cannot be supported by strong evidence. In this editorial, we highlight some of the risk mitigation strategies implemented at our institutions across Canada during the first wave of covid-19, and we discuss the considerations that should be made when managing patients during the second wave and beyond.
Keywords: coronavirus; covid-19; multiple myeloma coronavirus; covid-19; multiple myeloma

Share and Cite

MDPI and ACS Style

Foley, R.; Kaedbey, R.; Song, K.; Venner, C.P.; White, D.; Doucette, S.; Christofides, A.; Reece, D.E. Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations. Curr. Oncol. 2020, 27, 270-274. https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.7149

AMA Style

Foley R, Kaedbey R, Song K, Venner CP, White D, Doucette S, Christofides A, Reece DE. Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations. Current Oncology. 2020; 27(5):270-274. https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.7149

Chicago/Turabian Style

Foley, R., R. Kaedbey, K. Song, C.P. Venner, D. White, S. Doucette, A. Christofides, and D.E. Reece. 2020. "Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations" Current Oncology 27, no. 5: 270-274. https://0-doi-org.brum.beds.ac.uk/10.3747/co.27.7149

Article Metrics

Back to TopTop